Neu differentiation factor (NDF) is a 44-kD glycoprotein which was isolated from ras-transformed rat , applied once at the time of wounding, induced a highly significant increase in both epidermal migration and epidermal thickness at doses ranging from 4 to 40 ,ug/cm2. In contrast, rhNDF-al, rhNDF-pl, and rhNDF-132 had no apparent biologic effects in this model. rhNDF-a2 also induced increased neoepidermal expression of as and a6 integrins, two of the earliest integrins to appear during epidermal migration. In addition, rhNDF-a2-treated wounds exhibited increased neoepidermal expression of cytokeratin 10 and filaggrin, both epidermal differentiation markers. NDF a isoforms were expressed in dermal fibroblasts of wounded and unwounded skin, while both HER-2/neu and HER-3 were expressed in unwounded epidermis and dermal adnexa. In wounds, HER-2/neu expression was markedly decreased in the wound neoepidermis while neoepidermal HER-3 expression was markedly upregulated. 
Introduction
Neu differentiation factor (NDF)' is a 44-kD glycoprotein which was isolated from ras-transformed rat fibroblasts and was shown to induce tyrosine phosphorylation of the HER-2/neu receptor on several human mammary adenocarcinoma cell lines (1, 2) . A human homologue of NDF, termed heregulin, was independently isolated from conditioned medium of MDA-MB-231 human mammary carcinoma cells and was shown to induce tyrosine phosphorylation of the HER-2/neu receptor in MCF-7 human mammary carcinoma cells (3) . When NDF/heregulin was originally identified, it was believed to be the specific ligand for the HER-2/neu receptor. More recent studies have shown, however, that two recently isolated members of the epidermal growth factor receptor (EGFR) family, HER-3 and HER4 (4) (5) (6) , are the actual specific receptors for NDF/heregulin (7) (8) (9) and that HER-2/neu is tyrosine phosphorylated through activation of either the HER-3 or HER4 receptor by NDF/heregulin (7) (8) (9) .
NDF is a member of the EGF family of growth factors, a family which includes transforming growth factor-a (TGF-a), amphiregulin, betacellulin, heparin-binding EGF-like growth factor, and vaccinia virus growth factor (10) (11) (12) (13) (14) . Within the EGF growth factor family, only NDF has been shown to activate HER-2/neu (1, 2) . In addition, NDF does not bind to EGFR (1, 3) , while all other known EGF family members bind EGFR (13, 15) .
There are at least six distinct NDF precursor proteins (proNDFs), which are identical in their first 213 amino acid residues. This 213-amino acid stretch includes a basic NH2 terminus which is proteolytically cleaved at amino acid 14 in naturally occurring rat NDF, an immunoglobulin-like domain, a spacer domain, and two disulfide loops of a receptor binding EGF-like domain (16) . These proNDFs give rise to at least 12 different isoforms of NDF which arise by alternative splicing of a single NDF gene (16) . Isoform structural variation arises in three domains which COOH-terminally flank the identical 213 amino acid residues (16) . The domain and gives rise to isoforms 1-4. Lastly, variability in the length of the cytoplasmic tail determines isoforms a, b, and c (16) (Fig. 1) .
Some NDF isoforms display partial tissue specificity. ProNDF-a2 is the predominant isoform in mesenchymal cells, including fibroblasts, while proNDF-/31 is the major isoform in nervous tissue (16) . Several other NDF isoforms were originally cloned from nervous tissue and later were found to represent splice variants of NDF. These molecules include a group of Schwann cell mitogens collectively termed glial growth factors (17) and a factor, termed acetylcholine receptor inducing activity (ARIA), which stimulates acetylcholine receptor synthesis at the neuromuscular junction ( 18) .
Although the HER-2/neu receptor is not the specific receptor for NDF, NDF's biologic effects are mediated through tyrosine phosphorylation of HER-2/neu via HER-3 and HER-4 tyrosine phosphorylation in cells which coexpress both receptors (7, 9) . Both HER-2/neu and HER-3 are distributed over a relatively wide range of epithelial tissues, including the skin (19) (20) (21) , while precise tissue localization of HER- 4 has not yet been done. Immunohistochemical studies have localized both HER-2/neu and HER-3 to the basal and suprabasal layers of the epidermis (19, 21, 22) , as well as to epidermal adnexa (20, 21) . NDF has been shown to be expressed in the skin of embryonic mice by in situ hybridization, although the specific cell type could not be discerned (23) . The coexpression of NDF and both the HER-2/neu and HER-3 receptors in the skin, coupled with the ability of NDF to arrest proliferation and induce differentiation in a human breast carcinoma cell line overexpressing HER-2/neu (1) , suggests that the interaction of NDF with the HER-2/neu-HER-3 receptor complex may play an important role in the regulation of normal epidermal growth and differentiation.
To date, in vivo biologic activities have not yet been demonstrated for NDF, but EGF, TGF-a, and vaccinia virus growth factor have all been shown to variably stimulate in vivo wound reepithelialization (24) (25) (26) (27) (16, 23) , and then to compare the effects obtained using the NDF-a2 isoform with the effects observed with other NDF isoforms.
Methods
Recombinant NDF. Recombinant human NDF-a2 14-241 (rhNDF-a2), rhNDF-a1 14-249, rhNDF-,61 , and rhNDF-f32 14-238 were each produced in Escherichia coli, refolded, and purified to homogeneity by conventional techniques, and tested endotoxin free. Each isoform was determined to have bioactivity by its ability to induce tyrosine phosphorylation of p185u in MDA-MB453 human breast carcinoma cells at concentrations as low as 1 ng/ml (22 pM) (1), which was equivalent to the bioactivity of Chinese hamster ovary cell-derived rat NDF-a2 (16) .
Rabbit ear excisional wound model. Female, New Zealand White rabbits (3.5-4.0 kg) (Western Oregon Rabbit Co., Philomath, OR) were used for all experiments. The rabbit full thickness dermal wound model (27) was modified by removing cartilage in addition to the overlying epidermis and dermis (Fig. 2 ). In this model, the wound heals by sprouting of adnexa from the opposite side of the ear as well as by migration of epidermal keratinocytes from the wound margins (28) . A 6-mm trephine was used to aseptically create four 0.25-cm2 wounds on each ear. Immediately after wounding of both ears, 5 ,ul of rhNDF-a2 at specified concentrations in phosphate-buffered saline (PBS), or anti-NDF mAb exhibited any cross-reactivity with EGF or TGF-a (Fig.  3) . HER-2/neu was detected by a specific anti-HER-2/neu mAb, clone HER 20 (mouse IgG2a), which was also produced and characterized using BlAcore and ELISA by the authors (data not shown).
Assessment of epidermal differentiation and integrin expression. Replicate paraffin-embedded and frozen sections of eight representative rhNDF-a2-treated wounds and eight control wounds were stained for filaggrin and cytokeratins 10 and 14 to assess epidermal differentiation and stained for a5 and a6 integrins to assess the extent of epidermal expression of these integrins. Slides were read, blinded, by a pathologist experienced in interpretation of immunohistochemical staining results (D. M. Danilenko), and subjectively evaluated on the intensity and extent of epidermal staining for each antigen evaluated. Each of the eight rhNDF-a2-treated wounds was then directly compared with the eight control wounds, and the number of rhNDF-a2-treated wounds exhibiting either greater intensity or extent (depending on the antigen evaluated) than the control wound exhibiting the greatest staining for each particular antigen (e.g., 7/8) was reported.
Results rhNDF-a2 increases reepithelialization and epidermal thickness. rhNDF-a2-treated wounds exhibited significantly increased reepithelialization (new epithelium) versus control wounds 5 d after wounding at doses ranging from 0.4 to 40 gg/cm2 (Fig. 4 A) . There was a dose-dependent increase in reepithelialization between 0 and 0.4 Lg/cm2, with higher doses not appreciably increasing reepithelialization. rhNDF-a2-treated wounds also exhibited a significant increase in the thickness of new epithelium (epithelial area) 5 d after wounding at doses ranging from 4 to 40 jg/cm2, with a dose-dependent increase evident at doses of 0.04 to 4 jLg/cm2 (Fig. 4 B) .
rhNDF-a2 also significantly increased reepithelialization and new epithelial area 4 d after wounding at a dose of 4 4g/ cm2, the only dose tested (data not shown). In contrast to the epidermal effects induced by rhNDF-a2, the other NDF iso- lial area 5 d after wounding (data not shown). There was no difference in granulation tissue area in any of the rhNDF isoform-treated wounds versus control wounds, indicating that the rhNDF effect was epithelial specific (data not shown).
rhNDF-a2 does not significantly increase epidermal proliferation. The number of proliferating basal and suprabasal keratinocytes labeled with BrdU was counted at three different time points: 30 h, 3 d (72 h), and 5 d (120 h) after wounding. There were no statistically significant differences in proliferating basal and suprabasal keratinocytes in control wounds versus wounds treated with rhNDF-a2 at any of the three time points at all tested doses, although there was a trend toward increased proliferation in both basal and suprabasal keratinocytes in rhNDFa2-treated wounds 30 h after wounding (Table I) .
rhNDF-a2-treated wounds exhibit increased neoepidermal expression ofdifferentiation markers. Immunoperoxidase staining for filaggrin and cytokeratins (CK) 10 and 14 revealed that seven of eight rhNDF-a2-treated wounds exhibited increased expression of filaggrin and CK1O, both markers of epidermal terminal differentiation (31, 32) , in the neoepidermis migrating across the wound bed when compared with control wounds. This increased expression of filaggrin and CK1O in rhNDF-a2-treated wounds was largely confined to the oldest neoepidermis at the wound margins, although in some rhNDF-a2-treated wounds (those nearly or fully reepithelialized) filaggrin was expressed in nearly all of the neoepidermis (Fig. 5, C and F) . CK14, a marker of basal keratinocytes (32) , was expressed to the same extent in the regenerating epidermis of both rhNDFa2-treated and control wounds (Fig. 5, G and H) .
rhNDF-a2 upregulates epidermal integrin expression. Since rhNDF-a2 induced marked epidermal migration across the wound bed, and both EGF and TGF-a promote in vitro keratinocyte migration on collagen via increased keratinocyte expression of the collagen binding a2/31 integrin (33), we investigated whether the accelerated migration induced by rhNDF-a2 might be due to increased epidermal integrin expression. 20 , and HER-3, as detected by mAb RTJ.1, were both expressed by epidermal and follicular keratinocytes, but exhibited markedly different levels of expression in wounded versus unwounded epidermis. HER-2/neu was expressed predominantly on keratinocytes in the basal cell layer and lower stratum spinosum of unwounded epidermis as well as in the basal epithelium of dermal adnexa (Fig. 7 A) . In migrating wound neoepidermis, HER-2/neu expression was markedly decreased as detected by decreased immunoperoxidase staining intensity in both rhNDF-a2-treated and control wounds (Fig. 7 B) . HER-3 was weakly expressed by basal keratinocytes in normal epidermis, but was strongly expressed by follicular keratinocytes in the hair bulb and inner root sheath as well as by follicular keratin (Fig. 7 C) . In contrast to HER-2/neu expression, which markedly decreased in the neoepidermis, HER-3 expression was markedly increased in all keratinocytes of the migrating neoepidermis in both control and rhNDF-a2-treated wounds (Fig.  7 D) .
NDF as detected by both the a isoform-specific mAb, 1H7A, and by lH8C, which detects both a and ,B NDF isoforms, was expressed by dermal fibroblasts within and adjacent to the wound bed (Fig. 7, E and F ). There were no differences in NDF expression in rhNDF-a2-treated wounds versus control wounds.
Discussion
In this study, we have shown that rhNDF-a2, but not rhNDFa,, rhNDF-13l, or rhNDF-f32, accelerates epidermal migration with normal epidermal differentiation but does not induce significant sustained keratinocyte proliferation in rabbit partial thickness excisional wounds. These epidermal effects contrast those described for two other members of the EGF family, EGF and TGF-a, both of which induce marked keratinocyte proliferation but do not stimulate normal keratinocyte differentiation (38, 39) . In addition, both EGF and TGF-a inhibit the growth of hair follicles (40, 41) , while EGF stimulates the growth of sebaceous (42) and sweat glands (43) . In contrast, rhNDF-a2 has no apparent effect on any dermal adnexa, both in the rabbit ear excisional wound model and after systemic administration to neonatal rats (Danilenko, D. M., and G. F. Pierce, unpublished data).
The epidermal effects of rhNDF-a2 are also in contrast with those induced by other growth factors having paracrine epidermal effects. Keratinocyte growth factor, a member of the fibroblast growth factor family (44), induces marked proliferation but less extensive epidermal migration than does rhNDF-a2 (28) . Also in contrast with rhNDF-a2, keratinocyte growth factor directly stimulates hair follicles and sebaceous glands (28) . Other growth factors which have been reported to stimulate wound reepithelialization in vivo are basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF). bFGF directly stimulates keratinocyte growth in vitro (45) and has similar in vivo effects, namely epidermal proliferation and a moderate increase in epidermal migration (27) . PDGF does not appear to bind keratinocytes directly (46), but acts on the epidermis indirectly, presumably via the stimulation of dermal fibroblasts to produce paracrine growth factors with epidermal effects (27) . In contrast with rhNDF-a2, both bFGF and PDGF stimulate epidermal proliferation (27) .
TGF-fl has some effects on the epidermis and keratinocytes which are very similar to those of rhNDF-a2. Like rhNDF-a2, TGF-P does not induce prominent sustained epidermal proliferation and can actually inhibit the growth of cultured keratinocytes in vitro (47) . In addition, TGF-,B1 also appears to increase keratinocyte integrin expression, specifically integrins a5f3l and a,/5 (48) . Unlike rhNDF-a2, however, TGF-f3 decreases the rate of wound reepithelialization in vivo (27) and induces keratinocytes to assume a hyperproliferative phenotype in vitro (47) and to exhibit disorderly keratinization (dyskeratosis) in vivo (26), while rhNDF-a2-treated wounds exhibit normal differentiation. Therefore, in contrast with all other currently known 846 Danilenko et al. growth factors known to have effects on the epidermis, rhNDFa2 is unique in its ability to accelerate the migration of normally differentiated epidermis without stimulating sustained epidermal proliferation. In addition to demonstrating that rhNDF-a2 accelerates epidermal migration in vivo, we have also shown that rhNDF-a2 upregulates the distribution and expression of a5 and a6 integrins in the migrating neoepidermis. During epidermal migration and differentiation associated with wound repair, the distribution of integrins such as a2f3l, a3fil, and aj634 increases in the migrating new epidermis to extend into suprabasal layers, while the surface expression of other integrins, such as a5f1 and a, is markedly increased in migrating keratinocytes (49) (50) (51) . a5 integrin associates with the f31 subunit in keratinocytes, where it serves as a receptor for fibronectin (36) , one of the important components of the provisional extracellular matrix mediating keratinocyte migration in dermal wounds (52) . a5131 integrin is not expressed on normal, unactivated keratinocytes, but is upregulated in activated, migrating keratinocytes (50, 51, 53) . In keratinocytes, a6 integrin associates only with the /34 subunit and is localized within hemidesmosomes along the basal surface of unactivated basal keratinocytes where it serves as a Figure 5 . A, C, E, and G are serial sections of a control wound 5 d after wounding. B, D, F, and H are serial sections of a 5-d-old rhNDF-a2-treated wound. Original magnification, x20 for A and B and x25 for C-H. Arrow indicates wound margin. A and B are H&E stained and illustrate the marked increase in reepithelialization induced by rhNDF-a2 (B) versus control (A). C and D are stained for filaggrin, a marker of keratinocyte differentiation, and illustrate a marked increase in filaggrin expression in the migrating new epidermis of the rhNDF-a2-treated wound (D) versus the control wound ( C). E and F are stained for cytokeratin 10, another marker of keratinocyte differentiation, and illustrate an increase in cytokeratin 10 expression in the migrating new epidermis beyond the original wound margin (arrow) in the rhNDF-a2-treated wound (F) versus the control wound (E). G and H are stained for cytokeratin 14, a marker of undifferentiated keratinocytes, and illustrate that there are no differences in the expression of this marker in rhNDF-a2-treated wounds (H) versus control wounds (G). ; ' i h e ' & -t ' . r a w _ Figure 7 . Expression of HER-2/neu, HER-3, and two different epitopes of NDF in sections of rabbit ear. A and B are frozen sections stained for HER-2/neu expression, C and D are fixed sections stained for HER-3 expression, and E and F are frozen sections stained with two different anti-NDF mAbs. B, E, and F all illustrate the same ear wound. Original magnification, x50 for A and C, x20 for B, D, E, and F. Arrow indicates wound margin. A is normal skin and illustrates that HER-2/neu is expressed in basal and spinous layers of unwounded epidermis as well as in the basal layers of hair follicles and sebaceous glands. B is a wound margin and illustrates a marked decrease in HER-2/neu expression in wound neoepidermis. C is normal skin and illustrates that HER-3 is weakly expressed in unwounded epidermal basal keratinocytes, but is strongly expressed in basal layers of hair follicles and sebaceous glands as well as by follicular keratin. D is a wound margin and illustrates that wound neoepidermis exhibits a marked increase in both intensity and extent of HER-3 expression, in sharp contrast to the decreased neoepidermal expression of HER-2/neu illustrated in B above. E is a wound margin stained with the NDF a isoform-specific mAb, lH7A, and illustrates that dermal fibroblasts in both wounded and unwounded areas express a NDF isoforms. F is a wound margin stained with the mAb 1 H8C, which recognizes both a and 63 isoforms of NDF, and illustrates a pattern of localization virtually identical to that of 1H7A in dermal fibroblasts in both wounded and unwounded areas.
receptor for laminin (35, 54, 55 We have extended previous studies (19) (20) (21) (22) by demonstrating that HER-2/neu and HER-3 are both expressed in skin and dermal adnexa. We have also shown that HER-2/neu expression is markedly decreased in the migrating new epidermis, while neoepidermal HER-3 expression is markedly increased. These findings suggest that the interaction of rhNDF-a2 with the HER-2/neu-Her-3 receptor complex in wounded neoepidermis induces a conformational change in the receptor complex such that expression of its direct receptor, HER-3, is upregulated while expression of its indirect receptor, HER-2/neu, is downregulated. The biologic significance of this change in receptor expression is unclear, but indirect stimulation and/or inhibition of HER-2/neu has been reported to occur in vitro via the formation of heterodimeric receptor complexes between HER-2/neu and EGFR (56), HER-2/neu and HER-3 (8, 9) , and possibly between HER-2/neu and HER-4 (7) .
The finding that only rhNDF-a2 has an in vivo effect on dermal wound reepithelialization suggests that NDF-a2 is the predominant endogenous NDF isoform in skin and plays a unique role in mediating dermal-epidermal interactions during cutaneous tissue repair. It further suggests that the different NDF isoforms exhibit different in vivo biologic activities in addition to having differing patterns of cell and tissue distribution. The finding that /3 isoforms of NDF do not appear to have any in vivo biologic activity in cutaneous tissue repair is not altogether unexpected, since these isoforms have been localized primarily to nervous tissue (16) . The lack of in vivo biologic activity in our cutaneous tissue repair model with rhNDF-al, however, was somewhat unanticipated and suggests that the differing biologic activities of individual NDF isoforms extend beyond those attributable solely to the differences between a and /8 isoforms. Further studies in different in vivo model systems will be required to more fully delineate the biologic roles of the different NDF isoforms.
In summary, this study is the first report describing an in vivo biologic effect for NDF and demonstrates that NDF, and specifically NDF-a2, is unique among currently known growth factors in its epidermal effects. In addition, our results suggest that endogenous NDF-a2 may function as an important paracrine mediator in directing initial epidermal migration during cutaneous tissue repair.
